OSMITROL 20% IN WATER Drug Patent Profile
✉ Email this page to a colleague
When do Osmitrol 20% In Water patents expire, and what generic alternatives are available?
Osmitrol 20% In Water is a drug marketed by Baxter Hlthcare and is included in one NDA.
The generic ingredient in OSMITROL 20% IN WATER is mannitol. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the mannitol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OSMITROL 20% IN WATER?
- What are the global sales for OSMITROL 20% IN WATER?
- What is Average Wholesale Price for OSMITROL 20% IN WATER?
Summary for OSMITROL 20% IN WATER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 178 |
| Clinical Trials: | 6 |
| DailyMed Link: | OSMITROL 20% IN WATER at DailyMed |
Recent Clinical Trials for OSMITROL 20% IN WATER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| CPR Pharma Services Pty Ltd, Australia | Phase 1 |
| Celtaxsys, Inc. | Phase 1 |
| Clinical Network Services | Phase 1 |
Pharmacology for OSMITROL 20% IN WATER
| Drug Class | Osmotic Diuretic |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for OSMITROL 20% IN WATER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | OSMITROL 20% IN WATER | mannitol | INJECTABLE;INJECTION | 013684-003 | Approved Prior to Jan 1, 1982 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Baxter Hlthcare | OSMITROL 20% IN WATER IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 013684-007 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for OSMITROL 20% IN WATER
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pharmaxis Europe Limited | Bronchitol | mannitol | EMEA/H/C/001252 Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. |
Authorised | no | no | no | 2012-04-13 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
